Cancer immunotherapy and preclinical studies: why we are not wasting our time with animal experiments.
about
Ultrasound-stimulated drug delivery for treatment of residual disease after incomplete resection of head and neck cancer.Tumor masses support naive T cell infiltration, activation, and differentiation into effectorsOncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer.Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase.Progression of cancer from indolent to aggressive despite antigen retention and increased expression of interferon-gamma inducible genesVasculature Disruption Enhances Bacterial Targeting of Autochthonous TumorsVascular endothelial-targeted therapy combined with cytotoxic chemotherapy induces inflammatory intratumoral infiltrates and inhibits tumor relapses after surgery.A systematic analysis of experimental immunotherapies on tumors differing in size and duration of growthCytoreduction surgery reduces systemic myeloid suppressor cell populations and restores intratumoral immunotherapy effectiveness.Induced sensitization of tumor stroma leads to eradication of established cancer by T cells.Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgeryFas expression by tumor stroma is required for cancer eradication.Intralymphatic mRNA vaccine induces CD8 T-cell responses that inhibit the growth of mucosally located tumoursA positive-margin resection model recreates the postsurgical tumor microenvironment and is a reliable model for adjuvant therapy evaluation.CD8+ T cells targeting a single immunodominant epitope are sufficient for elimination of established SV40 T antigen-induced brain tumors.Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer.Chemo-immunotherapy induces tumor regression in a mouse model of spontaneous mammary carcinogenesis.Personalized immune-interception of cancer and the battle of two adaptive systems--when is the time right?Targeting cancer-specific mutations by T cell receptor gene therapy.IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers.Tumour ischaemia by interferon-γ resembles physiological blood vessel regression.Permissive expansion and homing of adoptively transferred T cells in tumor-bearing hosts.The immune system prevents recurrence of transplanted but not autochthonous antigenic tumors after oncogene inactivation therapy.Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs.Visualizing the dynamic of adoptively transferred T cells during the rejection of large established tumors.Making and circumventing tolerance to cancer.
P2860
Q30415659-05DBE331-99D3-4A2E-89E4-D4470008A222Q30433292-EA47F1BB-23E0-4AAF-ACA3-52321FF018F0Q34102216-ED66AB15-A3BF-49E8-93CA-BF7DC7F39BCAQ34243372-01DF576E-7D8B-49D1-89C1-F807612613ADQ35079913-083D261E-84A3-4DB1-9F29-CEBC440916AEQ35942173-0851D30C-3777-47FE-84FA-0A0663752321Q35949793-EF37F2C8-BB1D-4CB7-BE23-7535157A27E8Q36038477-DBCCF877-580C-4CC2-87BB-FED57ABB7BD1Q36161355-1F701F06-1323-49C1-BB39-52273FFE32C8Q36228950-5F20DE3F-3ED3-49D6-9FB4-48B79F6A6F1CQ36583022-A9228C4B-F9B7-4002-A963-2E221394C9F4Q36598412-A3637D34-AA99-44B4-B297-89A9E9FD17AFQ36638606-5B443375-8342-43DE-9B7C-0F9871BB4C06Q36710130-4084B61E-3771-41CA-90D5-B4A1961D17E2Q37074414-C6F70C30-AD75-4417-9977-0651241313D6Q37492464-52017261-2D4D-4065-B11B-B8A80F7D4987Q37644937-5481BFEA-5157-4523-91F4-2ADE4054707BQ38076107-D360DE3D-869A-4BC0-AC11-9D5EB9741F58Q38366556-643217FE-17B4-42FB-8EDA-398D76F25847Q40006095-9C15657D-8C86-4A81-9E6E-13DC99EC447FQ41493082-56965970-8AD2-428F-BDD5-12CF1311F0F5Q41588248-D1269BD1-6372-4E4A-95ED-ACC0B3CAD3C9Q47917004-09182A62-8569-46C2-8215-F307180DA84DQ48319918-96E82322-2822-4AD3-9C26-ED5DF64813DFQ50993575-0A0D1E8B-56D3-4CCA-B1E8-786507F96E82Q52909563-482D931A-350B-4712-9975-5EB2E239E949
P2860
Cancer immunotherapy and preclinical studies: why we are not wasting our time with animal experiments.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Cancer immunotherapy and precl ...... time with animal experiments.
@ast
Cancer immunotherapy and precl ...... time with animal experiments.
@en
type
label
Cancer immunotherapy and precl ...... time with animal experiments.
@ast
Cancer immunotherapy and precl ...... time with animal experiments.
@en
prefLabel
Cancer immunotherapy and precl ...... time with animal experiments.
@ast
Cancer immunotherapy and precl ...... time with animal experiments.
@en
P2093
P1476
Cancer immunotherapy and precl ...... time with animal experiments.
@en
P2093
Donald A Rowley
Gert Riethmüller
Hans Schreiber
Karin Schreiber
P304
P356
10.1016/J.HOC.2006.03.001
P577
2006-06-01T00:00:00Z